| Not Yet Recruiting | the Five-year Antibody Persistence After Immunization With IPV, MMR and HepA-L Vaccines NCT07338851 | China National Biotec Group Company Limited | — |
| Recruiting | Risk Assessment of Community Spread of Multiple Endemic Infectious Diseases in a One Health Perspective NCT07358910 | Institut Pasteur du Cambodge | — |
| Not Yet Recruiting | Prospective Clinical Registry for Evaluation of Exanthematous Infections and Coinfections NCT07112846 | Hospital Israelita Albert Einstein | — |
| Not Yet Recruiting | Non-interference Study of MR and Yellow Fever Vaccines Among Bangladeshi Infants Aged 9-12 Months NCT06815835 | International Centre for Diarrhoeal Disease Research, Bangladesh | Phase 3 |
| Completed | Immunogenicity of Japanese Encephalitis Vaccine Co-administered With Measles-Mumps-Rubella Vaccine (MMR) NCT06331702 | Liaoning Chengda Biotechnology CO., LTD | Phase 4 |
| Unknown | Immunity in Persons Fully Vaccinated Against Measles, Mumps and Rubella and Responses to Booster Vaccination NCT05894395 | University of Zurich | Phase 3 |
| Unknown | Co-administration Study of OCV, TCV and MR NCT05771779 | International Centre for Diarrhoeal Disease Research, Bangladesh | Phase 3 |
| Unknown | Immunogenicity and Safety of an Inactivated SARS-CoV-2 Vaccine Coadministered With Two Attenuated Vaccines NCT05952505 | Shanghai Municipal Center for Disease Control and Prevention | Phase 4 |
| Unknown | The Immunogenicity and Safety of the Vaccination of Human Papillomavirus Vaccine and Measles-Mumps-Rubella Vac NCT05279248 | Zhejiang Provincial Center for Disease Control and Prevention | Phase 4 |
| Completed | Measles and Rubella Vaccine Microneedle Patch Phase 1-2 Age De-escalation Trial NCT04394689 | Micron Biomedical, Inc | Phase 1 / Phase 2 |
| Completed | Study to Evaluate the Immunogenicity, Reatogenicity and Safety of Double Viral Vaccine (MR) for Measles and Ru NCT03148990 | The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz) | Phase 2 / Phase 3 |
| Completed | Measles-Rubella Vaccine Immunogenicity at 6 and 9 Months of Age NCT03071575 | Centers for Disease Control and Prevention | Phase 4 |
| Completed | Immunogenicity and Safety of Japanese Encephalitis Vaccine When Given With Measles-Mumps-Rubella (MMR) Vaccine NCT02880865 | PATH | Phase 4 |
| Completed | Study on Immunization Schedule of Beijing Tiantan Biological's Measles-mumps-rubella(MMR) Vaccine NCT03160820 | Centers for Disease Control and Prevention, China | Phase 4 |
| Completed | Study to Evaluate Safety and Imunogenicity of Double Viral Vaccine (MR) for Measles and Rubella NCT02196285 | The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz) | Phase 1 |
| Completed | Immunogenicity of Co-administration of Measles and Japanese Encephalitis Vaccines NCT02643433 | Centers for Disease Control and Prevention, China | Phase 4 |
| Completed | Search for the Measles Vaccine Virus Excretion in Breast Milk of Breastfeeding Women After Postpartum Vaccinat NCT02325310 | Assistance Publique - Hôpitaux de Paris | Phase 4 |
| Completed | Study of Immunogenicity, Reactogenicity and Safety of the Combined Measles, Mumps and Rubella Vaccine Produced NCT01991899 | The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz) | Phase 3 |
| Completed | Immunogenicity and Safety of GSK Biologicals' Combined Measles-mumps-rubella Vaccine in Volunteers, Seven Year NCT02058563 | GlaxoSmithKline | Phase 3 |
| Withdrawn | Safety Study of Measles-Mumps-Rubella-Varicella (MMRV) Vaccine, Priorix-Tetra™ in Children Living in the Phili NCT01738841 | GlaxoSmithKline | — |
| Completed | Consistency Study of GlaxoSmithKline (GSK) Biologicals' MMR Vaccine (209762) (Priorix) Comparing Immunogenicit NCT01702428 | GlaxoSmithKline | Phase 3 |
| Completed | Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Combined Measles-mumps-rubella (MMR) Vac NCT01681992 | GlaxoSmithKline | Phase 3 |
| Completed | Comparative Study of the Immunogenicity of MMR (Measles, Mumps and Rubella) Single Dose and Multidose Presenta NCT01777529 | The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz) | Phase 4 |
| Completed | Safety, Tolerability, and Immunogenicity of Measles, Mumps, Rubella, and Varicella (MMRV) Vaccine Made With an NCT01536405 | Merck Sharp & Dohme LLC | Phase 3 |
| Completed | Immunogenicity and Safety Study of PriorixTetra™ When Co-administered With Conjugated MenC Vaccine in Healthy NCT01506193 | GlaxoSmithKline | Phase 3 |
| Completed | Making Decisions About the Measles-Mumps-Rubella Vaccine NCT01369394 | University of Michigan | N/A |
| Completed | Study of Japanese Encephalitis Chimeric Virus Vaccine Given With Measles-Mumps-Rubella Vaccine in Taiwanese To NCT01188343 | Sanofi Pasteur, a Sanofi Company | Phase 3 |
| Completed | Measles, Mumps, and Rubella (MMR) Immunity in College Students NCT00962819 | Sri Edupuganti, MD MPH | — |
| Completed | Comparison of GSK Measles-mumps-rubella-varicella (MMRV) Vaccine Versus PriorixTM NCT00969436 | GlaxoSmithKline | Phase 3 |
| Completed | Immunogenicity of GSKs' MMR Vaccine (209762) vs. M-M-R® II, When Given With Routine Vaccines at 12-15 Months o NCT00861744 | GlaxoSmithKline | Phase 2 |
| Completed | Immunogenicity & Safety Study of GSK Biologicals' 208136 Vaccine Formulated With New Measles and Rubella Worki NCT00892775 | GlaxoSmithKline | Phase 2 |
| Completed | Immunogenicity & Safety Study of GSK Biologicals' Combined Measles-mumps-rubella-varicella Vaccine 208136 NCT00751348 | GlaxoSmithKline | Phase 3 |
| Completed | Serological Study in Children 12 to 23 Months Vaccinated With MMR (Measles, Mumps and Rubella) NCT01874457 | The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz) | — |
| Unknown | The Influence of Probiotics on the Immunologic Response to Vaccinations in Infants NCT00645996 | Assaf-Harofeh Medical Center | N/A |
| Terminated | A Study of ProQuad™ in Healthy Children in Korea (V221-023) NCT00839917 | Merck Sharp & Dohme LLC | Phase 3 |
| Completed | Comparative Study of Immunogenicity and Safety of a 2-dose Regimen of ProQuad® Manufactured With rHA (V221-038 NCT00566527 | Merck Sharp & Dohme LLC | Phase 3 |
| Completed | Immunogenicity and Safety of GlaxoSmithKline Biologicals' MMRV Vaccine vs. ProQuad® in Children 12-14 Months o NCT00578175 | GlaxoSmithKline | Phase 2 |
| Completed | Safety Study of ProQuad® rHA in Infants (V221-037) NCT00560755 | Merck Sharp & Dohme LLC | Phase 3 |
| Completed | Study of the Safety of Menactra® Vaccine When Administered With Other Pediatric Vaccines to Healthy Toddlers NCT00483574 | Sanofi Pasteur, a Sanofi Company | Phase 3 |
| Completed | Hepatitis A Vaccine, Inactivated and Measles, Mumps, Rubella and Varicella Virus Vaccine Live Safety Study (V2 NCT00326183 | Merck Sharp & Dohme LLC | Phase 4 |
| Unknown | Seroimmunity 2007 and Sub Study of the Swedish Population Regarding Vaccine Preventable Disease NCT00932269 | Swedish Institute for Infectious Disease Control | — |
| Completed | Immunogenicity and Safety Study of Proquad® and Infanrix® Hexa When Administered Concomitantly (V221-035) NCT00432042 | Merck Sharp & Dohme LLC | Phase 3 |
| Completed | Immunogenicity and Safety of Pediatric Vaccines When Administered With Menactra® in Healthy Toddlers NCT00422292 | Sanofi Pasteur, a Sanofi Company | Phase 3 |
| Completed | ProQuad® Intramuscular vs Subcutaneous NCT00402831 | Merck Sharp & Dohme LLC | Phase 3 |
| Completed | A Study of 2 Doses of Menactra®, a Meningococcal Conjugate Vaccine in Healthy Toddlers NCT00384397 | Sanofi Pasteur, a Sanofi Company | Phase 3 |
| Completed | Immunogenicity and Safety of Hepatitis A Vaccine Given at the Same Time of Measles, Mumps, Rubella Combined Va NCT00313950 | Sanofi Pasteur, a Sanofi Company | Phase 4 |
| Completed | Rubella Susceptibility in Multiparous Women NCT00401505 | Unity Health Toronto | — |
| Completed | Immunogenicity, Safety of Measles-mumps-rubella-varicella Vaccine (MeMuRu-OKA) Compared to Priorix™ Given With NCT00352898 | GlaxoSmithKline | Phase 2 |
| Completed | Immunogenicity, Safety of Measles-mumps-rubella-varicella Vaccine (MeMuRu-OKA) Compared to Priorix™ Given With NCT00353288 | GlaxoSmithKline | Phase 2 |
| Completed | Immunogenicity/Safety of Measles-Mumps-Rubella-Varicella Vaccine (MeMuRu-OKA): Using Two Different Administrat NCT00351923 | GlaxoSmithKline | Phase 3 |
| Completed | V221 Concomitant Use Study With Pneumococcal Conjugate Vaccine (V221-019) NCT00109343 | Merck Sharp & Dohme LLC | Phase 3 |
| Completed | Immunogenicity and Safety of a Combined Vaccine to Prevent Measles, Mumps, Rubella and Chickenpox Diseases NCT00127010 | GlaxoSmithKline | Phase 3 |
| Terminated | Immune Responses to Two Dose Varivax +/- MMR-II NCT00258726 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 1 / Phase 2 |
| Completed | Immunogenicity and Safety of a Combined Vaccine to Prevent Measles, Mumps, Rubella and Chickenpox Diseases NCT00127023 | GlaxoSmithKline | Phase 3 |
| Completed | Immunogenicity and Safety of Combined Vaccine to Prevent Measles, Mumps, Rubella and Chickenpox Diseases NCT00126997 | GlaxoSmithKline | Phase 4 |
| Completed | Safety Study of a Refrigerator-stable Formulation of VARIVAX® NCT00432731 | Merck Sharp & Dohme LLC | Phase 4 |
| Completed | Long-term Follow-up on Immunogenicity & Safety of Measles-Mumps-Rubella-Varicella (MMRV) Combined Vaccine NCT00406211 | GlaxoSmithKline | Phase 3 |
| Terminated | Responses of Premature Infants to Measles-Mumps-Rubella (MMR) and Varicella Vaccines NCT00138255 | National Institute of Allergy and Infectious Diseases (NIAID) | — |
| Completed | MMR and Varicella Vaccine in Premature Infants NCT00156559 | University of Rochester | — |
| Completed | Study to Evaluate Frozen Versus Refrigerated MMRV (Combined Measles, Mumps, Rubella, and Varicella) Investigat NCT00092430 | Merck Sharp & Dohme LLC | Phase 3 |
| Completed | Safety, Tolerability, and Immunogenicity of an Investigational Vaccine With Recombinant Human Albumin (rHA) in NCT00092404 | Merck Sharp & Dohme LLC | Phase 2 |
| Completed | Assess GSK Biologicals' MMR Vaccine (Priorix) When Given to Healthy Children at the Age of 12 to 18 Months in NCT00388440 | GlaxoSmithKline | Phase 4 |
| Completed | A Study of ProQuad in Healthy 4 to 6 Year Old Children (V221-014) NCT00985166 | Merck Sharp & Dohme LLC | Phase 3 |
| Completed | Frozen ProQuad Administered Concomitantly Versus Nonconcomitantly With Other Pediatric Vaccines NCT00984295 | Merck Sharp & Dohme LLC | Phase 3 |
| Completed | Safety, Tolerability, and Immunogenicity of 3 Frozen ProQuad Consistency Lots in Healthy Children (V221-012)(C NCT00985153 | Merck Sharp & Dohme LLC | Phase 3 |
| Completed | ProQuad Dose Selection Study (V221-011)(COMPLETED) NCT00986232 | Merck Sharp & Dohme LLC | Phase 2 |
| Completed | A Study of An Approved Vaccine at Mumps Expiry Potency in Healthy Children 12 to 18 Months of Age (V205C-007)( NCT00092391 | Merck Sharp & Dohme LLC | Phase 3 |
| Completed | ProQuad™ Versus M-M-R II™ and VARIVAX™ in Healthy Children (V221-009)(COMPLETED) NCT00975507 | Merck Sharp & Dohme LLC | Phase 3 |